(Q36141226)

12 August 2017

1 reference

title

A synthesis of cost-utility analysis literature in infectious disease (English)

1 reference

12 August 2017

5

Dan Greenberg

1 reference

12 August 2017

7

Peter J Neumann

1 reference

12 August 2017

2

Bruce R Schackman

1 reference

12 August 2017

Patricia W Stone

1

1 reference

12 August 2017

Christopher P Neukermans

series ordinal

3

1 reference

12 August 2017

Natalia Olchanski

series ordinal

4

1 reference

12 August 2017

Allison B Rosen

series ordinal

6

1 reference

12 August 2017

1 June 2005

1 reference

Lancet Infectious Diseases

12 August 2017

1 reference

12 August 2017

5

1 reference

12 August 2017

6

1 reference

12 August 2017

383-391

1 reference

The state of infection surveillance and control in Canadian acute care hospitals

12 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Modeling the costs of hospital-acquired infections in New Zealand

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Economic evidence for evidence-based practice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Can the value choices in DALYs influence global priority-setting?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Measuring the burden of disease: healthy life-years

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Understanding DALYs (disability-adjusted life years)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Cost-utility in practice: a policy maker's guide to the state of the art.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Measuring costs in cost-utility analyses. Variations in the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Toward quality assurance in QALY calculations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Making economic evaluations respectable

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Growth and quality of the cost-utility literature, 1976-2001.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

The quality of reporting in published cost-utility analyses, 1976-1997.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Intraclass correlations: uses in assessing rater reliability

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Forming inferences about some intraclass correlation coefficients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

A bibliometric analysis of health economics articles in the economics literature: 1991-2000

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Cost-utility analyses of clinical preventive services: published ratios, 1976-1997.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Systematic overview of cost-utility assessments in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Cost-effectiveness league tables: valuable guidance for decision makers?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Economic evaluation of vaccination programs: the impact of herd-immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Antimicrobial resistance: cost and containment.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Over-the-counter antimicrobials: the hidden costs of resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

An ounce of prevention ... what are the returns? Second edition, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Evidence based? Caveat emptor!

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Medicare's national coverage decisions, 1999-2003: quality of evidence and review times

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Design, analysis and presentation of multinational economic studies: the need for guidance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Varicella vaccination in England and Wales: cost-utility analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Cost-effectiveness of ribavirin plus interferon alpha-2b for either interferon relapsers or non-responders in chronic hepatitis C: a Japanese trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

New BMJ policy on economic evaluations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970142-0

7 January 2021

10.1016/S1473-3099(05)70142-0

Identifiers

DOI

1 reference

12 August 2017

1 reference